Literature DB >> 16797529

Hypertrophic response of Duchenne and limb-girdle muscular dystrophies is associated with activation of Akt pathway.

Angela K Peter1, Rachelle H Crosbie.   

Abstract

Dystrophic muscle undergoes repeated cycles of degeneration/regeneration, characterized by the presence of hypertrophic fibers. In order to elucidate the signaling pathways that govern these events, we investigated Akt activation in normal and dystrophic muscle. Akt is activated in neonatal muscle and in actively dividing myoblasts, supporting a developmental role for Akt signaling. Akt activation was detected at very early, prenecrotic stages of disease pathogenesis, and maximal activation was observed during peak stages of muscle hypertrophy. Duchenne muscular dystrophy patients exhibit a similar pattern of Akt activation. Mice with sarcoglycan-deficient muscular dystrophy possess more severe muscle pathology and display elevated Akt signaling. However, the highest levels of Akt activation were found in dystrophin-utrophin-deficient muscle with very advanced dystrophy. We propose that Akt may serve as an early biomarker of disease and that Akt activation mediates hypertrophy in muscular dystrophy. Current investigations are focused on introducing constitutively active and dominant-negative Akt into prenecrotic mdx mice to determine how early modification of Akt activity influences disease pathogenesis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16797529     DOI: 10.1016/j.yexcr.2006.04.024

Source DB:  PubMed          Journal:  Exp Cell Res        ISSN: 0014-4827            Impact factor:   3.905


  34 in total

1.  Enhancing muscle membrane repair by gene delivery of MG53 ameliorates muscular dystrophy and heart failure in δ-Sarcoglycan-deficient hamsters.

Authors:  Bo He; Ru-hang Tang; Noah Weisleder; Bin Xiao; Zhenhua Yuan; Chuanxi Cai; Hua Zhu; Peihui Lin; Chunping Qiao; Jianbin Li; Christina Mayer; Juan Li; Jianjie Ma; Xiao Xiao
Journal:  Mol Ther       Date:  2012-02-07       Impact factor: 11.454

Review 2.  What do mouse models of muscular dystrophy tell us about the DAPC and its components?

Authors:  Charlotte Whitmore; Jennifer Morgan
Journal:  Int J Exp Pathol       Date:  2014-09-30       Impact factor: 1.925

3.  Repression of phosphatidylinositol transfer protein α ameliorates the pathology of Duchenne muscular dystrophy.

Authors:  Natassia M Vieira; Janelle M Spinazzola; Matthew S Alexander; Yuri B Moreira; Genri Kawahara; Devin E Gibbs; Lillian C Mead; Sergio Verjovski-Almeida; Mayana Zatz; Louis M Kunkel
Journal:  Proc Natl Acad Sci U S A       Date:  2017-05-22       Impact factor: 11.205

4.  Genetic deletion of trkB.T1 increases neuromuscular function.

Authors:  Susan G Dorsey; Richard M Lovering; Cynthia L Renn; Carmen C Leitch; Xinyue Liu; Luke J Tallon; Lisa DeShong Sadzewicz; Abhishek Pratap; Sandra Ott; Naomi Sengamalay; Kristie M Jones; Colleen Barrick; Gianluca Fulgenzi; Jodi Becker; Kevin Voelker; Robert Talmadge; Brandon K Harvey; Ryan M Wyatt; Elizabeth Vernon-Pitts; Chao Zhang; Kevan Shokat; Claire Fraser-Liggett; Rita J Balice-Gordon; Lino Tessarollo; Christopher W Ward
Journal:  Am J Physiol Cell Physiol       Date:  2011-10-05       Impact factor: 4.249

5.  Muscular dystrophy in PTFR/cavin-1 null mice.

Authors:  Shi-Ying Ding; Libin Liu; Paul F Pilch
Journal:  JCI Insight       Date:  2017-03-09

6.  Reduced IGF signaling prevents muscle cell death in a Caenorhabditis elegans model of muscular dystrophy.

Authors:  Kelly Hyunju Oh; Hongkyun Kim
Journal:  Proc Natl Acad Sci U S A       Date:  2013-11-04       Impact factor: 11.205

7.  PTEN contributes to profound PI3K/Akt signaling pathway deregulation in dystrophin-deficient dog muscle.

Authors:  Marie Feron; Laetitia Guevel; Karl Rouger; Laurence Dubreil; Marie-Claire Arnaud; Mireille Ledevin; Lynn A Megeney; Yan Cherel; Vehary Sakanyan
Journal:  Am J Pathol       Date:  2009-03-05       Impact factor: 4.307

8.  DOCK3 is a dosage-sensitive regulator of skeletal muscle and Duchenne muscular dystrophy-associated pathologies.

Authors:  Andrea L Reid; Yimin Wang; Adrienne Samani; Rylie M Hightower; Michael A Lopez; Shawn R Gilbert; Lara Ianov; David K Crossman; Louis J Dell'Italia; Douglas P Millay; Thomas van Groen; Ganesh V Halade; Matthew S Alexander
Journal:  Hum Mol Genet       Date:  2020-10-10       Impact factor: 6.150

Review 9.  Therapeutic targeting of signaling pathways in muscular dystrophy.

Authors:  Shephali Bhatnagar; Ashok Kumar
Journal:  J Mol Med (Berl)       Date:  2009-10-09       Impact factor: 4.599

10.  Muscle inactivation of mTOR causes metabolic and dystrophin defects leading to severe myopathy.

Authors:  Valérie Risson; Laetitia Mazelin; Mila Roceri; Hervé Sanchez; Vincent Moncollin; Claudine Corneloup; Hélène Richard-Bulteau; Alban Vignaud; Dominique Baas; Aurélia Defour; Damien Freyssenet; Jean-François Tanti; Yannick Le-Marchand-Brustel; Bernard Ferrier; Agnès Conjard-Duplany; Klaas Romanino; Stéphanie Bauché; Daniel Hantaï; Matthias Mueller; Sara C Kozma; George Thomas; Markus A Rüegg; Arnaud Ferry; Mario Pende; Xavier Bigard; Nathalie Koulmann; Laurent Schaeffer; Yann-Gaël Gangloff
Journal:  J Cell Biol       Date:  2009-12-14       Impact factor: 10.539

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.